Host: |
Rabbit |
Applications: |
WB/IF/ICC/ELISA |
Reactivity: |
Human/Mouse/Rat |
Note: |
STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
Clonality: |
Polyclonal |
Conjugation: |
Unconjugated |
Isotype: |
IgG |
Formulation: |
PBS with 0.01% Thimerosal, 50% Glycerol, pH 7.3. |
Purification: |
Affinity purification |
Concentration: |
Lot specific |
Dilution Range: |
WB:1:500-1:2000IF/ICC:1:50-1:200ELISA:Recommended starting concentration is 1 Mu g/mL. Please optimize the concentration based on your specific assay requirements. |
Storage Instruction: |
Store at-20°C for up to 1 year from the date of receipt, and avoid repeat freeze-thaw cycles. |
Gene Symbol: |
DDX31 |
Gene ID: |
64794 |
Uniprot ID: |
DDX31_HUMAN |
Immunogen Region: |
652-851 |
Specificity: |
Recombinant fusion protein containing a sequence corresponding to amino acids 652-851 of human DDX31 (NP_073616.6). |
Immunogen Sequence: |
EIKMEDILCVLTRDDCFKGK RWGAQKSHAVGPQEIRERAT VLQTVFEDYVHSSERRVSWA KKALQSFIQAYATYPRELKH IFHVRSLHLGHVAKSFGLRD APRNLSALTRKKRKAHVKRP DLHKKTQSKHSLAEILRSEY SSGMEADIAKVKKQNAPGEP GGRPLQHSLQPTPCFGRGKT LKWRKTQKGVQRDSKTSQKV |
Tissue Specificity | Weakly or undetectably expressed in normal organs. Up-regulated in renal cell carcinoma. |
Function | May have DNA helicase activity and RNA helicase activity. Probably have ssDNA and RNA dependent ATPase activity. Plays a role in ribosome biogenesis and TP53/p53 regulation through its interaction with NPM1. |
Protein Name | Atp-Dependent Dna Helicase Ddx31Dead Box Protein 31HelicainProbable Atp-Dependent Rna Helicase Ddx31 |
Cellular Localisation | NucleusNucleolusColocalized With Npm1 In The Nucleoli |
Alternative Antibody Names | Anti-Atp-Dependent Dna Helicase Ddx31 antibodyAnti-Dead Box Protein 31 antibodyAnti-Helicain antibodyAnti-Probable Atp-Dependent Rna Helicase Ddx31 antibodyAnti-DDX31 antibody |
Information sourced from Uniprot.org
12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance